about
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraMelphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma NetworkDeregulation of MUM1/IRF4 by chromosomal translocation in multiple myelomaA validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.Phase II study of sorafenib in patients with relapsed or refractory lymphoma.A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaTreatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.Do new century catalysts unravel the mechanism of stereocontrol of old Ziegler-Natta catalysts?Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trialsHigh XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomibPhase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.Allogeneic transplantation for lymphoma: long-term outcome.Allogeneic transplantation for Hodgkin's lymphoma.SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.Current state of art for transplantation paradigms in peripheral T-cell lymphomas.Autologous stem cell transplantation for T-cell lymphomas.Experts' considerations on HLA-haploidentical stem cell transplantation.Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects.Detection of immunoglobulin gene rearrangement of B cell non-Hodgkin's lymphomas and leukemias in fresh, unfixed and formalin-fixed, paraffin-embedded tissue by polymerase chain reaction.Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation.Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
P50
Q28072397-3C201CC9-CB7C-43C3-BAE6-72A288E130F3Q28220911-FA6ED8C3-340F-4449-B189-D5112A252CF2Q28250998-D4E92EF2-BB53-4F00-BE19-BA8B700DC795Q31883517-A3938775-B173-479F-B484-7FFE432DD8BAQ33387698-A290624A-B135-4549-9F2F-3091915397D8Q33401136-FD922919-3341-488B-90DD-C7EE0142C2FEQ33405134-C69D6010-B21C-4C60-90A2-C21870B62E7CQ33409866-B31BBDB5-89CB-4AEA-8E73-C9F01E6F96B3Q33417756-250FCAC8-6A7F-435B-9E10-94E6DB2CFDE7Q33417762-5E6CE2FD-2B14-4CBD-A352-F251C9E1655EQ33420273-B0569FB3-2296-4EBB-8C3E-5DFB9DAA8DFAQ33431457-2FBF065D-AF3C-49A1-977B-0DA92C79139EQ33432492-8817CC09-9FB5-4732-AAE4-CDB2F9A2CE99Q34197491-9C0B8E77-5320-4631-95BB-DAECE8BA531DQ34222228-DD222014-DE24-41E8-8446-427C5066273CQ34314825-153D5B71-E538-4561-BCA7-B1FEE76FCB09Q34769213-5D3D4E69-F8C2-4626-94AD-473CCFF9015FQ35584266-DF037AFA-CFED-4CC5-A16E-CCC339FBF782Q36166896-880C6689-7847-4D28-957E-26ED61763DC8Q36654926-DA2C2225-A87A-43AA-88CA-ED8425DC8625Q36967098-F0C7474B-A534-4684-8E50-95DAAAFBA09FQ37060652-BE76126E-83A8-496C-A166-25F4EDEF81D3Q37552101-8C3269F3-95EC-4569-BBE4-B08D19BAD052Q37641045-35316739-8A95-4E64-8ADA-75B2529BBFE8Q37780662-DC0F2F08-1112-4001-8FF9-838F6A757A63Q37820685-C2C1390B-7089-4DC7-8BBF-0D523B0FC1A5Q38000078-8EFD90D0-6770-42E5-8A4B-B970968E9C03Q38132821-FAC8494A-2E3F-447C-80EC-5018327CD108Q38182255-C5FCBFD8-B02F-48F3-99F1-F56782FB1FEDQ38198728-9A922804-4DD7-4255-8D09-B65188AF9F8CQ38209433-7C31B68C-C012-4A23-9008-7AB5C0DAAFE8Q38230693-37166D07-EA36-41D6-A6FC-3BFC80D32ADDQ38264356-BBD7F9BC-36F6-4224-95BF-75176AEC690FQ38337517-563E24F9-D69A-4BB0-83D3-5889FD619A1CQ38485630-53B526CE-13F4-4329-A706-E58FA2D4FAA7Q38551290-9F226338-69AA-4060-8C6F-98A1D2C13544Q38590296-C9BC3C75-CD8C-48BC-8959-0C649F5AB31CQ38788692-013F60C1-C6E3-4334-9F18-781A5AB8066EQ38819940-E2E95F56-F1D8-4B9E-A6AC-A30921ACB551Q38973358-CF0A41B1-AE38-480A-8CA1-5B996435BC39
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paolo Corradini
@ast
Paolo Corradini
@en
Paolo Corradini
@es
Paolo Corradini
@nl
Paolo Corradini
@sl
type
label
Paolo Corradini
@ast
Paolo Corradini
@en
Paolo Corradini
@es
Paolo Corradini
@nl
Paolo Corradini
@sl
prefLabel
Paolo Corradini
@ast
Paolo Corradini
@en
Paolo Corradini
@es
Paolo Corradini
@nl
Paolo Corradini
@sl
P108
P1053
N-7584-2017
P106
P1153
34569599100
P21
P31
P3829
P496
0000-0002-9186-1353